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ABSTRACT
Cone, Alan J. M.S., Department of Biological Sciences, Wright State University, 2016.
Fission Yeast as a Model Organism for FUS-Dependent Cytotoxicity in Amyotrophic
Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative motor neuron disease
that causes progressive paralysis and death by asphyxiation. There is no cure or effective
treatment; however, previous research has identified several genes that appear related to the
pathology of ALS. When mutated, these genes result in proteins that gain toxic functions
and disrupt normal cellular processes. Fused in Sarcoma (hFUS) is a human transcription
factor in the nucleus that binds to DNA and RNA. Mutations in hFUS are associated with
both familial and sporadic cases of ALS, frontotemporal lobar degeneration (FTLD), and
cancer. In ALS and FTLD, hFUS is mislocalized to the cytosol where it interacts with stress
granules and forms aggregates. This aggregation and cytotoxicity has been previously studied in budding yeast; however, study in fission yeast may provide unique information. Fission yeast has several genetic advantages over budding yeast for modeling mammalian cell
biology, such as 43% of genes contain introns and they posess a similar alternative splicing
mechanism. Mammalian and fission yeast cells also both contain microRNA as well as similar cell growth cycles. In this project, I established a fission yeast model of hFUS and showed
that hFUS is toxic when overexpressed in fission yeast. Both localization to the nucleus and
mislocalization to the cytosol occurred during overexpression of hFUS. In addition, fission yeast homologues to previously identified budding yeast toxicity suppression proteins
were able to suppress hFUS toxicity, suggesting the suppression mechanism is conserved.
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I. INTRODUCTION

NEURODEGENERATIVE DISEASE
Neurodegenerative diseases are characterized by dysfunction and death of neurons. These diseases have a major impact on the lives and wellness of patients, and
frequently involve muscular dysfunction, paralysis, drastic mood changes, or cognitive
impairment. Well-known examples of neurodegenerative diseases include Alzheimer’s,
Parkinson’s, Amyotrophic Lateral Sclerosis, and Huntington’s. In all of these diseases
protein aggregates are seen in degenerating neurons (Table 1). Some of the diseases may
have limited treatment, but no neurodegenerative disease has a cure. Another hallmark of
neurodegenerative disease is that typically only one type of neuron or few areas are affected while the rest of the nervous system is spared. This is of particular interest considering that mutated protein aggregates in several diseases can be detected throughout the
brain, even though there is only an obvious degeneration in one region. While incidence
rates across the entire population for neurodegenerative disease is 2%, the risk skyrockets to 20% at age 65[1-4]. Since it appears that neurodegenerative diseases have a similar
pathology, current literature suggests that if one disease mechanism can be identified for
one disease then that mechanism may be applicable to the other diseases, leading to a
burst of effective treatments, or even cures for these debilitating maladies.
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Table 1. Neurodegenerative diseases and their incidence rates.
Disease
Associated Genes
Aggregates
Alzheimer’s
Yes
APP, Presenilin, APOEε4
Parkinson’s
Yes
SNCA, PRKN, LRRK2
ALS
Yes
C9orf72, SOD1, FUS, TDP-43
Huntington’s
Yes
HTT

Global Pop.
2%
0.2%
0.005%
0.002%

>65 Pop.
11%
5%
4%
3%

Neurodegenerative diseases are fairly rare across the global population, however as people age,
especially above 65 years old the rates drastically increase such that almost one-fifth of people
will face disease. Global population rates are based on incidence rates for all ages combined,
while the older than 65 years old population is calculated based on the number of people with the
disease living in the United States[1-4]. Protein aggregation has been observed in every disease,
suggesting its potential role in disease.
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AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic Lateral Sclerosis (ALS) is the unifying name given to a set of related motor neuron diseases which appear to have a similar pathology, but differ in inheritance, age of onset, and progression. Motor neurons in the cerebral cortex and spinal
cord progressively degenerate, resulting in muscle atrophy and paralysis. Eventually,
those with ALS die from asphyxiation as the respiratory muscles become incapable of
movement,[5] while neurons outside of the motor cortex and spinal cord appear to be left
functioning. However, a few recent studies also suggest sensory neurons[6] and areas involved with grammar may be mildly affected[7], and certain mutations give rise to altered
gene expression in a number of areas[8-9]. After diagnosis, progression of the disease can
range from a few months to fifty years[10], although the majority of patients die within
39 months[5-6]. Ninety-five percent of cases are sporadic, meaning they are the first in
their family to have the disease, while five percent are familial[11], and there is a global
incidence rate of 5.4 per 100,000 people[3]. Since inherited types of ALS are clinically
indistinguishable from sporadic cases, researchers have focused on inherited cases in an
attempt to find a genetic cause within families that are prone to developing ALS.

GENETIC FACTORS OF ALS
While the exact mechanisms of disease are not clear, likely candidates include
protein aggregation, oxidative stress, and extracellular signaling. The majority of the
genetic mutations associated with ALS are autosomal dominant and directly related to
protein aggregates (Table 2). The most frequently mutated genes related to both familial
and sporadic ALS from most to least common are: C9orf72, SOD1, FUS, and TDP-43[12].
C9orf72 mutants contain a hexanucleotide repeat expansion (GGGGCC)n in the intron
3

before its translation start codon, which when spliced out forms RNAs that can undergo
translation themselves, even without their own start codon. This process likely results in
interference with protein function, potentially by sequestering and forming protein aggregates[13-14]. C9orf72 mutants are found in the majority of familial and sporadic cases with
a known genetic component; however, due to the nature of the mutation and its recent
discovery in 2011[13], studies are limited. SOD1 was the first gene associated with ALS,
linked to 14% of familial cases and up to 1% of sporadic cases[12]. SOD1 is normally able
to convert superoxide radicals to molecular oxygen and hydrogen peroxide, serving as a
critical antioxidant in cells[15]. Hypotheses quickly formed suggesting that ALS stemmed
from excessive oxidative stress since the critical antioxidant was mutated. However, further studies show otherwise, as mice without functional SOD1 are viable, although they
age faster[15], and many SOD1 mutants do not lose their enzymatic activity, suggesting
ALS pathology is more complicated [16]. TDP-43 and FUS were the next genes found to
be associated with ALS in 2006 and 2007 respectedly, and each are linked to 4% of familial and 1% of sporadic ALS cases[17-18]. FUS and TDP-43 are both RNA-binding proteins,
further supporting the hypothesis that ALS results from more than oxidative stress. FUS
is thought to play a role in ALS pathology when mutants mislocalize from the nucleus to
the cytosol and aggregate with prion-like properties[17]. Wild-type TDP-43 aggregates are
found in many cases of ALS, although they are not thought to be causative as these aggregates co-occur with aggregates formed by other mutated genes related to ALS [18]. However, mutant TDP-43 is associated with ALS pathology as it forms aggregates in absence
of mutations in other ALS-linked genes[18]. Loss-of-function TBK1 mutants, also appear
at an incidence rate of 4% in familial ALS cases, but in less than 1% of sporadic cases[19].
TBK1 is unique, as the majority of mutated genes associated with ALS show a gain of
4

toxic function rather than a loss of function[19]. Normally, TBK1 plays a role in autophagy mediation and physically interacts with optineurin, another protein associated with
neurodegenerative disease. When TBK1 is mutated, it loses its interaction with optineurin
required for mediating autophagy, leading to a disruption of homeostasis[19]. TUBA4A,
associated with ALS in 2014, codes for major components of microtubules and is associated with 1.1% of familial ALS and less than 1% of sporadic cases[20]. When TUBA4A is
mutated, Tubulin Alpha 4A Protein limits the ability of microtubules to repolymerize, resulting in a dysfunctional network of microtubules and cytosolic aggregates[20]. TUBA4A
continues the trend of other frequently-seen mutations of forming aggregates, however it
does not appear to influence RNA synthesis or processing as other mutants related to ALS
may (Table 2).
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Table 2. Genes related to at least 1% of familial Amyotrophic Lateral Sclerosis cases.
Gene[12][21-22]
Function[12][21-22]
Aggregates[22] RNA
fALS[3][12] sALS[3][12]
Guanine nucleotide
Yes[14]
Yes[14]
40%
7%
C9orf72
SOD1
TDP-43
FUS
TBK1
TUBA4A

exchange factor[23]
Critical antioxidant
RNA Metabolism
RNA Metabolism
Autophagy Mediator
Major component of

Yes[16]
Yes[17]
Yes[18]
Yes[19]
Yes[20]

Yes[9]
Yes[17]
Yes[18]
Yes[19]
No[20]

14%
4%
4%
4%
1.1%

1%
1%
1%
<1%
<1%

microtubules
Genes are listed from most to least common, with the majority related to abnormalities in RNA
processing or production, protein aggregation, and are autosomal dominant in inheritance. Familial ALS (fALS) has more cases with identified mutations than sporadic cases do, however sporadic ALS (sALS) is harder to pinpoint mutations in. Many of these proteins also form aggregates
themselves or are associated with wild-type TDP-43 and p62 inclusions.
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FUSED IN SARCOMA (FUS)
In 2006 and 2007, focus shifted to novel mutations in genes associated with RNA
processing, including hTDP-43[18] and hFUS[17]. hFUS contains an RNA-binding domain
with no known ALS-associated mutations, a zinc-finger motif, a transcriptional activation
domain with prion-like properties, and a proline/tyrosine nuclear localization sequence[17]
(Figure 1). The majority of mutations related to ALS are missense mutations that do not
cause a frame shift or truncate the protein (Table 3). The high mutation rate in the nuclear
localization sequence (NLS) suggests that cytotoxicity may come from mislocalization
and probably a gain of toxic function. If overexpressed, both wild-type and mutated
hFUS will mislocalize to the cytosol and can form aggregates[17][24-25]; however, mutated
hFUS will interact with stress granules to delay their assembly and accelerate their disassembly[26]. Mutations occur across the gene except in the RNA Recognition Motif and
Zinc Finger, again suggesting core function still persists, but a mutation elsewhere results
in new and toxic functionality. hFUS can be sequestered to the cytosol by excessive glutamate signaling, often a precursor to cell death in itself[27-28].
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Missense
Deletion
Insertion
Silent

SYGQ-rich, Prion-Like
Transcriptional activation domain

RGG
Rich

RNA Recognition
Motif

RGG
ZnF
Rich

RGG
Rich

PY
NLS

Figure 1. hFUS schematic and mutation histogram. ALS related mutation histogram paired with
functional domains of the hFUS protein[17]. The number of different mutations at a given amino
acid residue ranges from zero to five, and the most common type of mutation is missense followed by deletion with frameshift[29-37].
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Table 3. hFUS mutations and phenotypes.
Mutation
Type
Functional Domain
[29]
P18S
Missense Prion-Like / SYGQ Rich
S57X[30]
Y66Y[31]
S96X[32]
P106L[29]
S115N[29]
G144-Y149X[29]
G156E[30]
G171-G175X[33]
G174-G175[34]
G174-G175X[32]
G187S[29]
G191S[30]
G206S[32]
R216C[30]
G222insG[29]
G223-G226X[32]
G225V[30]
G230C[30]
G230X[29]
R234L[30]
R234C[30]
R244C[30]
M254V[20]
G399V[29]
S402-P411Xins-

Deletion
Silent
Deletion
Missense
Missense
Deletion
Missense
Deletion
Insertion
Deletion
Missense
Missense
Missense
Missense
Insertion
Deletion
Missense
Missense
Deletion
Missense
Missense
Missense
Missense
Missense
Deletion

GGGG[29]

and Inser-

S462F
M464I[29]
G466VfsX479[29]

tion
Missense
Missense
Deletion,

[29]

Phenotype
FALS, SALS

Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
Prion-Like / SYGQ Rich
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 1
RGG Rich Region 2
RGG Rich Region 2

FALS, SALS
SALS
FALS, Cognitive Impairment
ALS / FTLD
SALS
FALS
FALS with Dementia
ALS, Not Specified
FALS
FALS, ALS / FTLD
FALS
FALS
ALS / FTLD
FALS
FALS
FALS
FALS
FALS
SALS
FALS
FALS
FALS
ALS / FTLD
SALS
FALS

RGG Rich Region 3
RGG Rich Region 3
RGG Rich Region 3

FALS
SALS
SALS

Frameshift
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G472VfsX527[29]

Deletion/

RGG Rich Region 3

FALS

G474VfsX528

[29]

frameshift
Deletion/ RGG Rich Region 3

FALS

Y485AfsX514

[32]

frameshift
Deletion/ RGG Rich Region 3

FALS

R487C
G492EfsX527[29]

frameshift
Missense RGG Rich Region 3
Deletion/ RGG Rich Region 3

SALS
SALS

R495QfsX527

frameshift
Deletion/ RGG Rich Region 3

SALS

R495X[32]
R495EfsX527[32]

frameshift
Deletion RGG Rich Region 3
Deletion/ RGG Rich Region 3

FALS, SALS
FALS

G497AfsX527

frameshift
Deletion/ RGG Rich Region 3

FALS

frameshift
Deletion/ RGG Rich Region 3

SALS

frameshift
Deletion/ RGG Rich Region 3

FALS

frameshift
Deletion/ RGG Rich Region 3

SALS

G504WfsX12[29]

frameshift
Deletion/ RGG Rich Region 3

SALS

G507D
K510E[29]
K510R[29]
K510WfsX517[32]

frameshift
Missense
Missense
Missense
Deletion/

FALS, SALS
FALS
FALS
FALS

S513P
R514S[30]

frameshift
Missense NLS
Missense NLS

[29]

R502fsX15

G503WfsX12

[29]

[32]

[29]

D502EfsX516

[29]

[29]

[29]

[29]

RGG Rich Region 3
NLS
NLS
NLS

FALS
FALS, SALS
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R514G[35]
G515C[30]
E516V[29]
H517D[33]
H517Q[30]
H517P[29]
R518Xfs519[36]

Missense
Missense
Missense
Missense
Missense
Missense
Deletion/

R518K
R518G[29]
Q519IfsX527[29]

frameshift
Missense NLS
Missense NLS
Deletion/ NLS

FALS
FALS, SALS
FALS

Q519X
R521S[37]
R521C[32]
R521G[32]
R521H[32]
R521L[32]
R522G[30]
R524T[30]
R524W[29]
R524S[32]
P525P[31]
P525L[34]
X527YextX[29]
r.spl[32]

frameshift
Deletion
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Silent
Missense
Extension
Splicing

FALS, SALS
FALS
FALS, SALS
FALS, SALS
FALS, SALS
FALS, SALS
FALS
FALS
FALS
FALS
SALS
FALS, SALS
FALS
FALS

[30]

[29]

NLS
NLS
NLS
NLS
NLS
NLS
NLS

FALS
FALS
FALS, SALS
FALS
FALS
FALS
Juvenile ALS (SALS)

NLS
NLS
NLS
NLS
NLS
NLS
NLS
NLS
NLS
NLS
NLS
NLS
NLS
Splicing

Previously reported hFUS mutations, type of mutation, related domain, and type of ALS resulting
from the mutation.
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YEAST MODEL OF FUS CYTOTOXICITY
Cytotoxic behavior of hFUS has been demonstrated in budding yeast (Saccharomyces cerevisiae)[24-25]. Shulin Ju integrated a sequence coding for hFUS fused with Green
Fluorescent Protein (GFP) on the N-terminus into the budding yeast’s genome. Inducible
expression of hFUS could be controlled extracellularly by growing the yeast on medium
containing 2% galactose. Glucose represses expression while galactose activates it in a
tightly-regulated fashion by interacting with the bGAL1 promoter. This simple method
of induction makes the bGAL1 promoter a common choice for protein expression studies in budding yeast. When hFUS is expressed in budding yeast, the protein localizes to
the cytoplasm and forms aggregates that are visualized as punctate structures (Figure 2).
hFUS aggregates are then thought to play a role in cytotoxicity as spotting assays show
that in budding yeast even one integrated copy of hFUS is enough to be extremely toxic
(Figure 3). Aaron Gitler and colleagues performed similar experiments, notably showing
that hFUS will co-localize with p-bodies and stress granules, suggesting this interaction
is part of the pathology (Figure 4)[25]. In general, S. cerevisiae is a well established model
organism for science and recreation, with a long history of use; however, fission yeast
(Schizosaccharomyces pombe) offers several unique advantages (Tables 4-8), including
undergoing a cell cycle similar to mammalian cells[38-40], mammalian-like alternative
splicing mechanisms[41], and the presence of microRNA[39][41].
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GFP
GFP-FUS

Figure 2. FUS aggregates and mislocalizes in budding yeast. Localization and appearance of
GFP alone (top) and GFP-FUS (bottom) proteins are viewed via fluorescence microscopy. Differential interference contrast (DIC) microscopy was used to visualize the yeast cells. 4’,6-diamidino-2-phenylindole (DAPI) is a stain that binds to A-T rich regions of DNA to make the nucleus
fluoresce. GFP codes for a protein that fluoresces green and can be seen in fluorescence microscopy. GFP is expressed ubiquitously throughout the cell; however, when it is attached to FUS it
is unable to be localized to the nucleus, instead forming aggregates in the cytosol, as indicated by
several bright green spots (Adapted from Ju et al., 2011).
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Gene OFF

Gene ON

Figure 3. FUS is toxic when overexpressed in budding yeast. Ten-fold serial dilutions (most
to least concentrated yeast drops) with yeast containing one or two copies of FUS were grown on
glucose-containing and galactose-containing media. Galactose induces expression of FUS, which
results in the lethal phenotype. Pictures were taken after two days of growth at 30°C (Adapted
from Ju et al., 2011).
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Figure 4. FUS co-localizes with p-bodies and stress granules. Fluorescence microscopy images
showing the localization of FUS along with a p-body (A) or stress granule (B) markers strongly
suggest that FUS contributes to both p-body and stress granule composition. (A) Fluorescence
microscopy images showing FUS tagged with Yellow Fluorescent Protein (YFP), shown in green,
co-localizing with Dcp2, a p-body marker, tagged with Red Fluorescent Protein (RFP). Any areas
on the merged panel showing yellow suggests both proteins are in the same place. (B) Fluorescence microscopy image showing FUS tagged with YFP, shown in green, and stress granule
marker Pabp1 tagged with Cyan Fluorescent Protein (CFP), shown in blue. Light blue regain on
the merge suggest that both proteins are in the same location (Adapted from Sun et al., 2011).
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Table 4. Genetic makeup of S. cerevisiae and S. pombe.
Attribute
S. cerevisiae
Sequenced genome
Yes[42]
Chromosomes
16[42]
Number of Genes
~5,600[42]
Genes with Introns
5%[43]
Centromeres
Small[42][44]

S. pombe
Yes[43]
3[43]
~4,900[43]
43%[43]
Elongated with Repeats[43-44]

Both yeasts have a sequenced genome, however S. pombe contains many genes with introns while
S. cerevisiae only has relatively few.
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Table 5. Cell cycle attributes of S. cerevisiae and S. pombe.
Attribute
S. cerevisiae
Mitotic Spindle Present
G1/S to Division[39]
Chromosome Condensation
Little[39]
Cell Division Regulation
G1 to S[39]
Generation Time
1.25 - 2 hours[42]
Synchronize Cells Based on
Bud Emergence[39]
Cell Cycle Phase

S. pombe
M Phase[38]
Significant[39]
G1 to S and G2 to M[39]
2 - 4 hours[43]
Centrifugation as size indicates
age[39]

S. pombe has a cell cycle similar to the one found in mammalian cells, so labs with interests in
cell cycle regulation usually use S. pombe rather than S. cerevisiae as a model organism.
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Table 6. Transcription and translation attributes of S. cerevisiae and S. pombe.
Attribute
S. cerevisiae
S. pombe
[39]
Promoter Region Location
10 base pairs upstream
25-35 base pairs upstream[39]
Mammalian Promoter Active No[39]
Yes including HIV1, SV40, and
Yeast Artificial Chromosome
Human gene expression
Human gene substitution
Structure of Small Nuclear U2

Yes[39]
Yes
Yes
Similar to Fungi[39]

CaMV35S[39]
Yes[45-47]
Yes
Yes[48]
Similar to higher eukaryotes[49]

and U6 RNA
RNA 5’ Splicing Site
RNA 3’ End Formation

Similar to Fungi[39]
AT-Rich; lack AAUAAA

Like Mammals[39]
AT-Rich; lack AAUAAA mo-

Alternative Splicing
Codon usage
MicroRNAs

motif[39]
Similar to Fungi[50]
Similar to Fungi[53]
No / Not Detected

tif[39]
Similar to higher eukaryoes[50-52]
Similar to Fungi[53]
Yes[41][51]

[50]

S. pombe is similar to mammalian cells in its processes from initiation of gene transcription to
post-translational processing.
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Table 7. Signaling in S. cerevisiae and S. pombe.
Attribute
S. cerevisiae
Drug-Metabolizing Enzyme
Yes, 1% of Cell[39]

S. pombe
Yes, >10% of Cell[39]

Expression (cytochrome
P450)
Heat Shock Response

Heat Shock Factor constitu-

Heat Shock Factor responsive

tively bound to Heat Shock

to heat shock[54]

Recognition of ER retention

Element[54]
No[39]

Yes[39]

KDEL signal
Classic NLS Recognition
PY NLS Recognition

Yes[39]
No[24]

Yes[39]
Yes (this study)

Cellular stress studies and protein folding likely would differ based on the yeast used due to a
difference in the heat shock response.
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Table 8. Other properties of S. cerevisiae and S. pombe.
Attribute
S. cerevisiae
Commonly Used Inducible
Tight Control, in presence

S. pombe
Tight control, delayed repression

Promoter

of galactose using GAL1

(16 hours) with thiamine using

Age Determination
G-protein coupled receptor
Sexes
Switching Sex
Mating Induction
Mammalian-like apoptosis
Cell Fusion with Mouse

promoter[24-25]
Bud Emergence[39]
Limited[39]
a and a[56]
Both[56]
Rich Medium[39]
No[58]
No[39]

nmt promoter[55]
By Size[39]
Yes, can perpetuate signals[39]
h+, h-, and h90[39]
h90 only[57]
Nitrogen Starvation[39]
Yes[58-59]
Yes[39]

Cells
Current methods of working with yeast favor S. cerevisiae as it is more commonly used; however,
small changes to protocols can adapt them for S. pombe. S. pombe’s ability to utilize G-protein
coupled receptors, undergo a mammalian-like apoptosis, and fuse with mouse cells suggests that
many characteristics of S. pombe are conserved in mammalian systems.
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FISSION YEAST
Budding yeast are a commonly used model with a wide range of protocols and
genetic tools while fission yeast models typically have methods derived from budding
yeast versions. Despite a lack of established protocols, the genetic and cellular advantages of fission yeast provide reason to increase their use as a model for studying neurodegenerative disease-related proteins. Presence of introns, alternative splicing machinery,
and microRNA allow fission yeast to regulate and alter gene expression at more levels
than just transcription and translation, along with higher precision. Similar to mammals,
fission yeast produce alternatively spliced mRNAs. Fission yeast also contain a wellformed Golgi apparatus[39] permitting post-translational modifications such as prenylation
and addition of a terminal galactose, resulting in profound differences in the localization
of proteins[60]. As an example, assume there is a gene that codes for the word and punctuation “Awesome.” Budding yeast would be able to translate this to always make the word
“Awesome.” If that “Awesome” gene however is set up so the DNA is “Awe-[intron]some”, then fission yeast would be able to transcribe that same gene into “Awe,” “Some,”
and “Awesome.” In addition to the alternative forms, a greater number of possible
post-translational modifications in fission yeast could change “Awesome” to “Awesome!”
or “Awesome?” resulting in profoundly different versions of the same gene.

FISSION YEAST HOMOLOGUES OF ECM32, NAM8, & SKO1
After assessing cytotoxicity of hFUS, Ju and colleagues also performed a library
overexpression screen to identify budding yeast genes that when co-expressed with hFUS
would suppress hFUS cytotoxicity[24]. Ninety-five percent of the budding yeast genome
was screened, yet only a few genes appeared to suppress hFUS cytotoxicity, including
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bECM32, bNAM8, and bSKO1 (Tables 9 & 10). bECM32, a homologue to the human
protein hUPF1, is associated with nonsense mediated decay. bNAM8, which is potentially regulating the bGAL1 promoter rather than suppressing hFUS toxicity, has the human
homologue hTRNAU1AP which can bind to RNA but its exact function is not well
understood. bSKO1 is a transcription factor without a human homologue, however there
is a fission yeast homologue fATF1. Fission yeast also contain homologues to these genes
with equal or higher identity to human homologues as confirmed by Protein BLAST
(Figure 5). Functionality among the homologues in each organism is comparable, and
they appear to play similar roles, which is beneficial in determining how they manage to
suppress FUS cytotoxicity. Shulin Ju also performed a Western Blot to see if suppression
was caused by altered hFUS expression, but with every suppression gene, hFUS protein
level was not significantly changed, suggesting another mechanism is responsible for
toxicity suppression[24].
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Table 9. Budding yeast genes that suppress cytotoxicity of hFUS.
Gene
Function
Human Homologue
Function
bECM32 Translation termination
UPF1
RNA Decay
bNAM8 RNA binding protein
TRNAU1AP
Unknown; RNA Binding
bSBP1
RNA Binding Protein
RBM14
Nuclear receptor coactivator
bSKO1
Transcription factor
None
N/A
bVHR1
Transcription activator
None
N/A
These genes are all able to suppress hFUS cytotoxicity when over expressed without altering the
levels of hFUS. Full-length hUPF1 and hUPF2 also rescue hFUS cytotoxicity in a budding yeast
model[24].
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Gene OFF

Gene ON

Figure 5. Expression of bECM32, bSBP1, bSKO1, and bVHR1 suppresses hFUS toxicity.
When both hFUS and rescue genes are expressed, hFUS toxicity is reduced. The mechanism of
how these genes suppress toxicity is unknown, but hFUS levels are not decreased and aggregates
still form (Adapted from Ju et al., 2011).
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Table 10. S. pombe and human homologues to S. cerevisiae toxicity suppression proteins.
Suppression Genes
Identity

S. cerevisiae
bNAM8
bSKO1
bECM32

S. pombe

H. sapiens

S. cerevisiae S. pombe to

S. cerevisiae

homologue homologue to S. pombe H. sapiens to H. sapiens
fCSX1
hTRNAU1AP 35% (5e-51) 44% (3e-40) 48% (2e-26)
fATF1
hATF2
44% (2e-07) 44% (2e-19) none[24]
fUPF1
hUPF1
34% (2e-61) 59% (0.0)
35% (7e-66)

S. pombe homologues to the genes identified in the S. cerevisiae screen add new possibilities to
finding and understanding the mechanism of how they are able to suppress FUS cytotoxicity,
along with uncovering relevant human homologues.

25

II. SPECIFIC AIMS
AIM 1: To establish fission yeast (S. pombe) as a model organism for FUS-dependent
cytotoxicity.
AIM 2: To assess the ability of S. pombe homologues of genes previously identified in S.		
cerevisiae to suppress FUS cytotoxicity.
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III. MATERIALS AND METHODS

FISSION YEAST STRAINS AND MAINTENANCE
Fission yeast strain tk7 / wild-type, provided as a generous gift from Dr. Yongjie Xu’s lab (Wright State University), was streaked out on Yeast Extract + Supplements
(YES) medium. Glycerol stocks were prepared by inoculating a toothpick full of fission
yeast in 5 mL liquid YES, growing overnight at 30°C and shaking at 11 x g, then the next
morning mixing 600 mL of liquid culture with 400 mL of 50% glycerol and storing the
mixture at -80°C. When selecting for fission yeast with a specific vector or maintaining
the vector, Edinburgh Minimal Medium (EMM) (Sunrise Science Products, San Diego,
CA) without leucine or adenine was used to grow the yeast.

VECTORS
S. pombe vectors pREP1, pREP41, and pREP81 (Figure 6) were provided as a
generous gift from Dr. Yong-jie Xu’s lab as either a bacterial culture containing the vector
or pure vector. A version of pREP1 with an adenine selective marker was provided by Dr.
Taro Nakamura (Osaka City University) as a pure vector. Pure vectors were transformed
into competent E. coli cells as previously described[61-62] and selected for by growing at
37°C overnight on Lysogeny broth (LB) with added ampicillin to a final concentration
of 100 mg / mL. The next day individual colonies were selected from the plate and inoculated in 5 mL of liquid LB with ampicillin overnight at 37°C, shaking at 11 x g. The
next morning, 600 mL of liquid culture was mixed with 400 mL 50% Glycerol and stored
at -80°C, and vector extraction was performed using QIAGEN (Germantown, MD)[63] or
Zymo Research (Irvine, CA)[64] miniprep kits.
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Leucine or
Adenine
Marker

Ampicillin
Resistance

pREP Series Plasmid
8776 Base Pairs
No Message
in Thiamine
Promoter
Multiple Cloning
Site
Figure 6. pREP Series Vector Map. The pREP series plasmids are 8.7 kb in length and contain a
leucine (leu2) or adenine (ade6) selective marker, ampicillin resistance gene, repressible promoter, and multiple cloning site. The ampicillin resistance enables bacteria containing the vector in
medium containing ampicillin. The leu2 and ade6 genes enable selection of yeast with the vector.
Since the genes code for proteins that can synthesize a missing required amino acid, only the
yeast that grow are those which have the vector. The no message in thiamine (nmt) promoter is
tightly controlled and repressed by adding 10 mM thiamine to growth media.
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MOLECULAR CLONING
hFUS, GFP-hFUS, fCSX1, fATF1, and fUPF1 were placed into pREP series
vectors for expression in S. pombe. hFUS was amplified out of the budding yeast vector
pRS303GAL1-FUS via a 25 mL polymerase chain reaction (PCR) using Pfu DNA polymerase with the forward primer CACAGTGTCGACATGGCCTCAAACGATTATACCC
and reverse primer CACATGGATCCTTAATACGGCCTCTCCCTGC to add SalI and
BamHI restriction sites respectively. In order to clone hFUS into pREP1 vector with the
ade6 gene, the alternative reverse primer CACATATTTAAATTAATACGGCCTCTCCCTGC was used to add a SwaI restriction site. After PCR, gel electrophoresis[65] was
done to verify that the DNA was properly amplified. In order to purify the new PCR product, Zymoclean Gel DNA Recovery Kit was used[66]. Once a pure product was obtained,
the product along with pREP1, pREP41, and pREP81 were digested with SalI (Promega)
for two hours in NEBuffer 3.1 (New England Biolabs), and then everything was cleaned
and concentrated with the Zymo Research DNA Clean & Concentrator kit[67] immediately after the restriction digest. The cleaned and concentrated DNA for each vector and
PCR product was then digested for two hours in BamHI-HF (New England Biolabs) in
NEBuffer 4.1 (New England Biolabs), or alternatively SwaI in NEBuffer 3.1 at 25°C
(New England Biolabs) for cloning into the adenine vector, and then cleaned and concentrated once more. At this point, typical concentration of the vectors was 75 ng/mL and
the gene was around 11 ng/mL. T4 DNA Ligation (New England Biolabs) was performed
at room temperature for two hours, or overnight for the adenine selection vector, using
a 3:1 molar ratio of vector to insert. After ligation, the new pREP1-FUS, pREP41-FUS,
and pREP81-FUS constructs were transformed into chemically competent E. coli cells[61],
plated on LB plates with ampicillin and grown overnight at 37°C. The next day, a single
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colony from each plate of without satellite colonies was inoculated in liquid LB with
ampicillin, grown at 37°C with shaking at 11 x g overnight. 600 mL of the liquid culture
was removed and used to make a 1 mL glycerol stock. The vector DNA was extracted
from the remaining 4.4 mL of culture using a QIAGEN Miniprep Kit[63]. Once the new
vectors had been purified, microplate DNA quantification readings were taken to assess
the concentration of each, typically between 200-800 ng/mL. Confirmation of successful
ligation of hFUS into the pREP vectors was done by a three hour restriction digest with
EcoRI (New England Biolabs) in NEBuffer 4.1 along with a PCR using the previously
listed primers.
In order to clone GFP-hFUS into the pREP series, two additional restriction
enzyme sites had to be added as all of the sites already on the pREP vector also existed in
either GFP or hFUS. The restriction enzyme sites NheI and BglII were selected as both
of those enzymes were available and recently purchased from New England Biolabs. A
25 mL PCR with pREP1 was done to amplify the multiple cloning site and add NheI and
BglII sites using forward and reverse primers CACATGGATCCGCTAGCCCGGGTAAAAGG and CACATGGATCTCAGATCTGCATTACTAATAGAAAGG respectively.
The 5’ end of the forward primer also included a BamHI site while the 5’ end of the
reverse primer included a SacI site so the amplified product could be digested then ligated
into the vectors. After PCR, the amplified DNA was excised from a gel and purified using
the Zymo Research Gel DNA Recovery kit[66], then the purified multiple cloning site
along with pREP1 was digested with BamHI-HF in NEbuffer 4.1 (New England Biolabs)
for two hours at 37°C. Following digestion, both the multiple cloning site and vector
were cleaned and concentrated[67], then digested with SacI in CutSmart Buffer (New
England Biolabs) for two hours then cleaned and concentrated as previously described.
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Using a 3:1 molar ratio of vector to insert, the new multiple cloning site was ligated into
pREP1 using T4 DNA Ligase at room temperature for two hours, followed by inactivation of the ligase at 65°C for 10 minutes prior to doing a transformation into chemically
competent E. coli. Transformants were grown, selected for, then glycerol stocks were
made as previously described in this document. Successful addition of restriction enzyme sites was verified by performing a two hour digest with NheI in CutSmart buffer
and another two hour digest with BglII in NEBuffer 3.1, then compared on a gel to pREP
without these sites. Both enzymes were able to linearize the new vector while leaving the
control untouched, indicating successful ligation.
GFP-hFUS was amplified out of the vector pDEST53-GFP-FUS via a 25 mL PCR
using the forward primer CACATGGCTAGCATGGCCAGCAAAGGAGAAG with a
NheI site and the reverse primer CACGTGAGATCTTTAATACGGCCTCTCCCTGC
with a BglII site. Successful amplification was confirmed by running a gel, and then as
before the DNA was excised from the gel and purified. Purified GFP-hFUS and pREP1
with added restriction enzyme sites were digested with NheI in CutSmart buffer (New
England Biolabs) for two hours, cleaned and concentrated, then digested with BglII in
NEBuffer 3.1. Another round of cleaning and concentrating was done prior to setting up
an identical T4 DNA Ligation and chemically competent E. coli transformation, selection, and vector purification as previously performed. GFP-hFUS was confirmed to be
in pREP1 by amplifying it out of the newly purified vector via PCR with the GFP-hFUS
primers and then running on it a gel.
Since fATF1, fCSX1, and fUPF1 were not available in the lab, they needed to
be amplified from genomic DNA. Genomic DNA extraction was performed with a single-tube Lithium Acetate (LiOAc)-SDS lysis as previously described[68]. fATF1, fCSX1,
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and fUPF1 were amplified using the primers and conditions described in Table 10. After
amplification, fATF1, fCSX1, and fUPF1 along with the pREP1 vector were digested in
the same reaction conditions as previously used for hFUS and GFP-hFUS, but using the
restriction enzymes mentioned in Table 10 for each gene, with XmaI digestion performed
in CutSmart buffer (New England Biolabs). After digesting with each restriction enzyme,
and cleaning and concentrating the DNA between and after digestions, fATF1, fCSX1, and
fUPF1 were ligated into pREP1 with T4 DNA Ligase, then transformed and amplified in
E. coli as done previously for hFUS and GFP-hFUS. After transformation, vectors were
extracted and purified from E. coli as before, and then confirmed with both a restriction
digest and PCR. Twenty-percent glycerol stocks were made upon confirmation of the
gene’s ligation into the vector.
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Table 11. Primers for fission yeast genes fATF1, fCSX1, and fUPF1.
Gene
Forward Primer
Reverse Primer
CACATTGTCGACATGTCGCAAGACCCGGGCTAGTACfATF1

Added Sites
SalI, XmaI

fCSX1

CCCGTCTCCCGTC
GCAGTCGTCGACATGTC-

CCTAAATTGATTCTTTGAGC
GCAAGACCCGGGTTATGAATC- SalI, XmaI

fUPF1

TATTGACTGCCTTTATCGC
GGAGTCGTCGACAT-

GCGTGACAAGC
AATCGAGGATC-

GTCTTTAGGGCTA-

CCTAGAACCTAGTAGGTTC-

CAACCTAATAAT

GTCGAACT

SalI, BamHI

These genes are the fission yeast homologues to budding yeast genes identified in a screening to
suppress hFUS cytotoxicity. fATF1 and fCSX1 were amplified with thirty cycles at an annealing
temperature of 58°C for thirty seconds and elongation step at 72°C for two minutes and thirty
seconds with a final extension time of three minutes. Due to its larger size, fUPF1 had the same
reaction parameters as fATF1 and fCSX1, except the extension time was three minutes and the
final extension time was three minutes and thirty seconds.
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YEAST TRANSFORMATION
Transforming S. pombe with pREP series vectors was done by adapting the
budding yeast One-Step Transformation Lithium Acetate method[69] to fission yeast. S.
pombe was grown overnight on a plate containing EMM. The next day, 90 mL of 50%
polyethylene glycol 3350 (PEG) and 10 mL of 1 M LiOAc was added to a 1.5 mL microcentrifuge tube. Fission yeast were then picked up on a toothpick from the EMM plate
and resuspended in the PEG and LiOAc solution. One microgram of DNA was added to
the 1.5 mL microcentrifuge tube, then the tube was briefly vortexed. The 1.5 mL microcentrifuge tube was then incubated at 43°C for 40 minutes with brief vortexing every 10
minutes. After incubation, the yeast were plated onto EMM dropout plates of the desired
selection amino acid (leucine or adenine) and thiamine if needed to repress gene expression, then placed in an incubator to grow at 30°C for four to six days. Once colonies
grew, they were picked up off of the plate and resuspended in 5 mL of the same type of
liquid growth medium and grown overnight to confirm the presence of vector.

YEAST CRUDE PROTEIN EXTRACTION
S. pombe was grown to the mid-exponential phase in liquid medium then normalized to an optical density (OD600) of 2 in 1 mL of H2O. The cells were then centrifuged
at 5,440 x g for two minutes, resuspended in 100 mL of 0.2 M NaOH, and incubated on
ice for 15 minutes. Once again the yeast was centrifuged at 5,440 x g for two minutes,
but then the pellet was resuspended in 100 mL of Yeast Protein Extraction Sample Buffer (2.4 mL 1 M Tris at a pH of 6.8, 20 mL 50% Glycerol, 8 mL 10% SDS, 4 mL of 1%
Bromophenol Blue, and 65.6 mL H2O for 100 mL of buffer). 0.4 mL of 2-mercaptoethanol was added, then the mixture was boiled for five minutes at 95°C followed by a brief
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vortexing and three minute centrifugation at 6,720 x g. The cells were then either stored
at -80°C or loaded directly into an acrylamide gel to minimize protease activity.

GEL STAINING AND WESTERN BLOT
Two gels each composed of a 4% acrylamide / bis-acrylamide (29:1) stacking gel
and 10% acrylamide / bis-acrylamide (29:1) separating gel were used to determine that
protein was extracted from yeast and confirm the expression of a specific protein. Protein
samples were loaded into the wells and the gel was run for five minutes at 50 volts, then
the voltage was increased to 150 volts until the PageRuler Plus ladder[70] reached the bottom of the gel.
One gel was then placed in a box with a flat bottom and Coomassie Blue gel
staining buffer was poured over it. The gel submerged in buffer was then shaken at room
temperature for two hours, at which point the staining buffer was replaced with new staining buffer after briefly washing the gel in water, and shaken again at room temperature for
two hours. The buffer was replaced one more time and the staining continued overnight.
In the morning, the staining buffer was removed and the gel was washed in water, then
destaining buffer (50 mL Acetic Acid, 100 mL Methanol, and H2O up to a final volume of
500 mL) was poured onto the gel and it was shaken at room temperature until the destaining buffer became blue, or for about one hour. The destaining buffer was then poured off
and fresh destaining buffer was added and the gel was shaken at room temperature for
another hour. This continued until the bands could clearly be seen and were distinct from
the background.
The other gel was placed in Towbin Buffer[71] for 15 minutes. Polyvinylidene fluoride (PVDF) was soaked with 100% methanol briefly, then washed in water and placed
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in Towbin Buffer for 15 minutes in order to equalize the osmolarity of both the gel and
membrane. Towbin buffer was poured inside the transfer box and both sponges were wet
before assembling the transfer sandwich so the gel was on the anode and membrane was
on the cathode side[72]. After placing the transfer sandwich in the transfer box, about 800
mL of Towbin Buffer was poured in to cover the transfer sandwich, which was run without interruption at 50 volts for two hours at room temperature.
The membrane was then rinsed in water and blocked in TBST with milk (5%
Powdered Milk, 1x TBS, and 0.1% Tween20)[72] for one hour of shaking at room temperature. After blocking, the primary antibody was added to fresh TBST and incubated
with rocking at 4°C overnight. The next morning, the membrane was rinsed with TBST
and shaken at room temperature for five minutes, then rinsed. This was repeated four
more times. After the final rinse, the secondary antibody was added to fresh TBST with
5% milk just covering the membrane and shaken for one hour at room temperature. As
before, five rinses for five minutes were done in TBST, then BCIP/NBT (WorldWide) was
poured onto the membrane and shaken at room temperature until bands developed.

SERIAL DILUTION AND SPOTTING ASSAY
Fission yeast transformed with a vector were grown overnight in 5 mL of liquid
selective EMM containing 10 mM Thiamine to repress vector gene expression. The next
day, the OD was read by measuring absorbance at 600 nm to estimate the concentration
of yeast cells. The higher the OD, the more yeast are present. Cells were washed with water and ODs were normalized to 3 by taking the multiplicative product of the desired final
volume and desired OD, then dividing by the measured OD. That number corresponds
to the volume of culture which needs to be centrifuged for three minutes at 12,100 x g to
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pellet cells which were then resuspended in the desired volume of water, thereby resulting
in the desired cell concentration. The ODs for all samples must be consistent, otherwise
phenotypes may simply be due to differing yeast concentrations among samples. The serial dilutions were set up by filling four tubes with 180 mL of H2O, then transferring 20 mL
by pipette from the tube with the immediately higher concentration of yeast to that tube,
mixing by pipetting up and down, and then doing the same for the next tube on down
(Figure 7). After the dilutions, starting with the least concentrated and going to the most
concentrated, 1.5 mL of each dilution was pipetted onto the proper agar plate and allowed
to dry before inverting the plate and incubating at 30°C. Plates were observed and photographed daily.

FLUORESCENCE MICROSCOPY AND IMAGING
Fluorescence microscopy and imaging were performed with a Nikon Eclipse
TE2000-S microscope and images were collected then analyzed using Meta Imaging Series 6.1. Slide preparation was performed by adding 5 mL of live culture of mid-log phase
yeast to a VWR VistaVision Microscope Slide, then placing a Gold Seal Cover Glass over
top, laying down one side and then carefully bringing the rest of the glass down as to prevent air bubble formation. The slide was then immediately taken to the microscope where
yeast cells were identified and viewed in the eyepiece. If the nucleus needed to be visualized, then 333 mL of overnight culture was added to a 1.5 mL microcentrifuge tube and
mixed with 666 mL of 100% Ethanol. The mixture was incubated at room temperature for
30 minutes and yeast were collected by spinning them down for one minute at 420 x g to
avoid displacing the nucleus. The pellet was then washed in 1x Phosphate-buffered saline
(PBS), then resuspended in 1 mL of 1x PBS with 0.5 mL of 4’,6-diamidino-2-phenylin37

dole (DAPI) stock at a concentration of 2.5 mg/mL. One drop of this solution was placed
onto a slide as previously described. Images were obtained using Meta Imaging Series
6.1 after exposing the samples to the laser in order to excite GFP or DAPI.
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Desired Volume (mL) x Desired Optical Density
Measured Optical Density

=

Volume of Original
Stock to Use (mL)

20 µL
10x Dilution Five Times

Centrifuge

Each Contains 180 µL Water
Figure 7. Serial dilution of fission yeast. Figure depicting the centrifugation and dilutions. This is
a standard method for assessing yeast phenotypes, and allows for observation of phenotype across
several logarithmic concentrations of yeast.
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IV. RESULTS

OVEREXPRESSION OF hFUS IS TOXIC IN FISSION YEAST
Fission yeast were transformed with the high (pREP1), medium (pREP41), or low
expression vectors (pREP81) containing hFUS and were selected on minimal medium
with 10 mM thiamine and no leucine. Serial dilutions were done with strains containing
one of the three expression levels of hFUS, or an empty pREP1 vector as a control, then
were spotted onto leucine dropout plates. The control plate also had 10 mM of thiamine to
repress expression of hFUS. At the highest expression level, similar to the budding yeast
model, hFUS is toxic to fission yeast, as demonstrated by weak to no growth in each spot
(Figure 8). The medium and low expression levels were less toxic than the high expression, but still showed limited growth compared to the control plate (Figure 8). The high
expression level is expected to be 300 times the medium expression level[73]. In order to
confirm expression of hFUS, a Western Blot was run with the crude extract from fission
yeast transformed with the pREP1 vector containing hFUS in the presence of 0 mM, 0.2
mM, and 10 mM thiamine, along with crude extract from S. cerevisiae with an integrated
copy of hFUS. The proteins were separated by electrophoresis on two gels, one of which
was stained with Coomassie Blue to determine the total amount of protein loaded, while
the other was transferred to a PVDF membrane for Western Blot analysis using an antibody specific to hFUS (Abcam, Cambridge, MA). As shown in Figure 9, hFUS is expressed at a level compareable to budding yeast. Thiamine repression worked as intended,
since only conditions with low concentrations or lacking thiamine showed hFUS protein
expression. These experiments have been repeated five times, confirming hFUS toxicity
in fission yeast.
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FUS LOCALIZES TO THE NUCLEUS AND CYTOSOL
Fission yeast transformed with pREP1 containing GFP-hFUS were grown overnight in synthetic medium with 10 mM thiamine and lacking leucine, then the next day
cells were centrifuged for three minutes at 420 x g and washed twice in H2O. After
washing, the pellet was resuspended in synthetic medium lacking leucine and thiamine
and grown overnight so GFP-hFUS could be expressed. The next morning the cells were
either fixed, or, for live imaging, 5 mL were placed on a microscope slide, and observed
under the Nikon Eclipse TE2000-S microscope at 40x and 60x. GFP-hFUS could be seen
both inside and outside of the nucleus (Figure 10). Aggregation was also observed. The
Western Blot and fluorescence microscopy data together suggest that hFUS is likely the
agent of cell death, as the protein is expressed and forms aggregates. To check whether
GFP-FUS is toxic, a spotting assay was performed. The addition of GFP to the N-terminus of hFUS does not appear to alter toxicity of hFUS (Figure 8).
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Figure 8. Expression of hFUS is toxic in fission yeast. The image on the left is of a minimal
medium plate lacking leucine and including 10 mM of thiamine so gene expression is repressed.
The image on the right also is of a minimal medium plate lacking leucine, but gene expression is
not repressed so hFUS should be expressed. The highest expression level vector shows clear toxicity as growth is limited compared to the other conditions, while the medium and low expression
levels showed clear, but less intense toxicity. Toxicity of GFP-hFUS on the high expression level
vector is comparable to the untagged high expression level of hFUS. Pictures were taken after
three days of growth at 30°C.
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Budding Yeast

Fission Yeast

pRS303Gal1FUS (Positive Control)
2% Galactose Induction

pREP1-FUS
0.2 mM

10 mM

ON

OFF

0 mM

Thiamine

70 KD

55 KD
ON

Figure 9. Westerm blot detecting hFUS expression in fission yeast. hFUS was detected in
every sample except pREP1-FUS in 10 mM thiamine, where it was expected and confirmed to be
repressed. The hFUS protein appears 62 KD, the expected size of hFUS. This confirms that hFUS
is expressed in fission yeast after induction.
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4 mM

Figure 10. hFUS localizes to the nucleus and cytosol, and forms aggregates. Fluorescence
microscopy image (40x) of fission yeast expressing GFP-hFUS (green). GFP-hFUS localizes to
the nucleus, appears to aggregate, and is also detected in the cytosol.
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FISSION YEAST HOMOLOGUES SUPPRESS TOXICITY
Fission yeast homologues fATF1, fCSX1, and fUPF1 to bNAM8, bSKO1, and
bECM32 respectively, were amplified by PCR from S. pombe genomic DNA and cloned
onto pREP1 vectors containing a leucine selection marker. To test for the ability of these
genes to suppress hFUS toxicity, first transformations were done of just the homologue
itself, empty vectors with leucine or adenine as a selection marker, and then each homologue on a pREP1 leucine selection vector paired with hFUS on a pREP1 adenine selection vector. fATF1 and fCSX1 when overexpressed by themselves are cytotoxic (Figure
11). fATF1 has a similar toxicity to hFUS while fCSX1 appears to be more toxic than
hFUS or fATF1. Overexpression of fUPF1 was not toxic to fission yeast. fATF1, fCSX1,
and fUPF1 when co-expressed with hFUS are able to suppress hFUS cytotoxicity (Figure
12). If fATF1,fCSX1, or hFUS are overexpressed alone they are toxic, but co-expression
suppresses toxicity of each protein. Presence of both vectors was confirmed by extracting
the vectors from fission yeast and successfully amplifying hFUS and each suppression
gene via PCR.
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pREP1 Empty Vector

pREP1-FUS

pREP1-ATF1

pREP1-CSX1

pREP1-UPF1

OFF

ON

Figure 11. fATF1 and fCSX1 are toxic in fission yeast. The picture of the plate on the left lacks
leucine and contains 10 mM thiamine to repress gene expression while the plate pictured on the
right has no leucine or thiamine to permit gene expression. From top to bottom, pREP1 empty
vector, hFUS, fATF1, fCSX1, and fUPF1 were spotted out to determine their toxicity when overexpressed. fATF1 and fCSX1 both appear to be toxic, as does hFUS. fATF1 has a toxicity similar
to hFUS, while fCSX1 is more toxic than either fATF1 or hFUS. fUPF1 is not toxic when overexpressed in fission yeast. Pictures were taken after four days of growth at 30°C.
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Figure 12. Co-expression of fATF1, fCSX1, or fUPF1 with hFUS suppresses toxicity. The
plate on the left lacks leucine and adenine, and contains 10 mM thiamine to repress gene expression while the plate on the right has no leucine, adenine or thiamine, allowing gene expression.
fATF1, fCSX1, and fUPF1 were able to partially suppress hFUS cytotoxicity, while hFUS also
was inversely able to partially suppress the toxicity of fATF1 and fCSX1. Interestingly, the results
indicate that the toxicity of fATF1, fCSX1, and hFUS are not additive, but instead appear to cancel each other out. Pictures were taken after three days of growth at 30°C.
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V. DISCUSSION

Neurodegenerative diseases affect 20% of individuals over the age of 65, and
share traits including protein aggregation and cell death, yet no cures exist. Treatments
are not particularly helpful and manage symptoms rather than treating the underlying
disease. Development of a unique model that allows for rapid screening and testing, but
contains the complexities of mammalian cells would help with understanding disease.
In my study, Schizosaccharomyces pombe (fission yeast) was tested and validated as a novel model organism for studying neurodegenerative diseases at the molecular
level, with the efficacy and accuracy provided by traditional systems like Saccharomyces
cerevisiae (budding yeast). Fission yeast, budding yeast, and humans all diverged one
billion years ago, and present day fission yeast and humans share a remarkable set of
traits. As a yeast, S. pombe is easily, quickly, and cheaply worked with, and shows strong
phenotypes. Benefits of fission yeast include similar promoters and cell cycle to mammalian cells, alternative splicing machinery, and microRNA. These traits make fission yeast
an advantageous model organism for studying human diseases. Information found from a
fission yeast system could then be tested and validated in higher models with confidence
that mechanisms will be conserved.

S. pombe AS A MODEL ORGANISM
S. pombe was used to generate a novel model organism for studying the neurodegenerative disease ALS, by assessing how the overexpression of the protein hFUS
impacted cell viability. Similarities and differences to the budding yeast model were seen,
which validates the generation and use of a new model. As in budding yeast, overexpres48

sion of wild-type hFUS is toxic to fission yeast and will localize to the cytosol where
it forms aggregates. In budding yeast, hFUS does not appear to significantly enter the
nucleus and remains in the cytosol[25], but in fission yeast hFUS will localize to the nucleus without significant presence of hFUS in the cytosol until aggregates form. This unique
difference allows further study to be done in fission yeast utilizing a mutated version of
hFUS found in ALS patients to see how the mutation affects localization, toxicity, and the
ability for toxicity to be suppressed by other proteins.
The level of toxicity by hFUS on an exogenous vector in fission yeast was similar
to the same condition in budding yeast[24]. The level of toxicity shown in the S. pombe
model allows screening for genes that suppress or enhance toxicity, hopefully aiding in
the understanding of the mechanism behind hFUS cytotoxicity. With the genetic advantages of fission yeast, it is also expected that additional proteins may be identified using
screens in S. pombe that cannot be found in S. cerevisiae screens.

fATF1, fCSX1, AND fUPF1
fATF1, fCSX1, and fUPF1 all are able to suppress toxicity induced by hFUS, suggesthing that the suppression mechanism is conserved between S. pombe and S. cerevisiae. Conversely, hFUS is able to suppress toxicity induced by the overexpression of fATF1
and fCSX1. Interestingly, when identifying and reviewing the fission yeast homologues to
the budding yeast suppression genes, they kept appearing together in publications, often
related to oxidative stress[74-77].
The human homologue of fCSX1 is not toxic when overexpressed in budding
yeast, but is toxic in neuronal cells (communication with the Barmada group, University of Michigan, unpublished data), which supports use of the fission yeast model since
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fCSX1 is toxic when overexpressed in S. pombe. fUPF1 by itself is not cytotoxic, consistent with the overexpression of budding yeast or human homologues bECM32 and
hUPF1 respectively. In budding yeast and human cells, hUPF1 is able to strongly suppress toxicity of hFUS. bUPF1 is unable to suppress toxicity, while bECM32 can. Work
should be performed to identify common qualities between bECM32, fUPF1, and hUPF1,
along with differences from bUPF1 in an attempt to understand how this suppression
occurs. Characterizing and assessing protein-protein interactions is a good place to start
as finding binding partners can give considerable information about how a mechanism or
pathway may work. Since hFUS levels do not decrease, likely the action of several proteins in a pathway work to limit the toxic effects when both the suppression protein and
hFUS are overexpressed.
Now with two models, budding and fission yeast, experiments on UPF1 can be
performed and confirmed in two models, thereby validating results quickly. A few places
to start include generating fragments of UPF1 or chimeric proteins to determine what
regions are required for toxicity suppression. Performing studies in yeasts with different
genes knocked out may also yield information on how suppression occurs. When comparing predicted protein interactions via STRING between bUPF1, fUPF1, hUPF1, and
bECM32, all four are predicted to interact with UPF2, UPF3, and DCP2, while only the
proteins that suppress toxicity, fUPF1, hUPF1, and bECM32, have a predicted interaction
with SUP35 homologues. Knocking out UPF2, UPF3, or both, will help pin down the
pathway that suppresses hFUS toxicity, as UPF1, UPF2, and UPF3 are involved in nonsense-mediated decay. If these knockouts result in UPF1 alone being unable to suppress
toxicity, then likely it suppresses through the nonsense-mediated decay pathway and not
just by an interaction with UPF1 itself. Alternatively, if this is not the case then another
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mechanism must be responsible, perhaps involving SUP35. SUP35 is a eukaryotic peptide chain release factor that interacts with bECM32, fUPF1, and hUPF1, but not bUPF1
suggesting the interaction with SUP35 is critical for suppressing toxicity. Unfortunately,
SUP35 is an essential gene, so a simple knockout study cannot be performed, and expression must be tightly controlled by another mechanism that enables the cell to grow until
the gene can be safely turned off.
These results validate S. pombe as a novel model organism. For experiments similar to those performed in S. cerevisiae, S. pombe appear to be a valid and useful model
organism for diseases previously successfully modeled in S. cerevisiae. Now with fission
yeast confirmed as a useful model, future studies can focus on using the genetic advantages including alternative splicing, microRNA, and greater number of post-translational
modifications to determine the impact that those processes have on cytotoxicity of disease
associated proteins. Introns, regulation by RNAs, and post-translational modifications
have been largely ignored when studying disease because it has not been easy or feasible
to do so. S. pombe now provide a system which is simple and cheap to grow, but retains
the advantages of far more complex and costly systems like human cell culture or mouse
models. Integrating full genomic hFUS, including introns, into the S. pombe genome
would shed light onto the role of hFUS on the alternative splicing of other genes and how
this influence may change with mutated hFUS. Currently, only hFUS complementary
DNA (cDNA) is used which is mRNA that has undergone reverse transcription back into
DNA. Problematically, this is a heavily modified version of the gene sequence that lacks
introns and the native 5’ or 3’ untranslated regions. These regions are functionally important for the regulation of proteins downstream, often via RNAs which are generated from
introns and may bind to these untranslated regions, typically to repress gene expression.
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With these added features in the model, assessing how the gene product of hFUS from
cDNA differs from hFUS from the genome, along with differences in other genes’ RNA
or protein expression between the two conditions could give great insight into how these
previously ignored genetic features may have a large impact on hFUS cytotoxicity, and
may lead to new research projects looking beyond protein aggregation and to how genetic
expression is altered. Understanding differences between RNA and protein expression in
control and disease models should highlight impacted pathways or potentially uncover
new ones. These pathways then ideally could be targeted by a compound or other therapy
rather than attempting to overexpress a gene as a treatment. Once a mechanism or even
potential toxicity suppressor is sufficiently identified in S. pombe, then the project could
be validated in human cell culture and mouse models, hopefully leading to better options
that translate from models to clinical trials.
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VI. CONCLUSION
Neurodegenerative diseases increase with age and, while exhibiting distinct
symptoms, frequently appear to have similar pathological mechanisms including protein
aggregation and cell death. Budding yeast are one model which has been used to study
neurodegenerative disease at a cellular and molecular scale because they are simple to
grow and handle, results are clear and occur quickly, and it is feasible to quickly screen
thousands of proteins for disease-related phenotypes. However, as more research demonstrates the potential role that mRNA, microRNA, and alternative splicing may play in
disease, fission yeast offer several advantages to this tried and true model. The current
alternative for a faithful representation of protein expression involves using human cell
culture, growing neurons, then overexpressing the protein of interest. While all of the
genetic advantages are in this system, phenotypes are not clearly observed. Large scale
experiments such as genetic screening may be technically possible, but are not feasible
due to the amount of money and time required for working with human cells. Fission
yeast, however, are cheap and provide comparatively rapid results, enabling large scale
experiments to be performed, while retaining genetic attributes similar to human cell
models. Data from fission yeast studies could then be validated in human cells, as fission
yeast would enable a shift from screening genes to studying a select identified few and
associated pathways in the context of ALS.
S. pombe is another kind of yeast shown to have the advantages of working with
budding yeast while also possessing genetic advantages of human cell culture. Complementing budding yeast models and possessing advantages of its own, fission yeast allow
for large-scale genetic screening and more accurate protein assessment to be done quickly
and cheaply. Fission yeast make a great model to study genetic and protein-linked diseas53

es. This study demonstrated fission yeast is a valid model organism for molecular studies
of neurodegenerative disease, which allows for future studies to obtain additional information using S. pombe’s genetic advantages. These future studies in the fission yeast will
hopefully increase the understanding of exactly how hFUS contributes to cytotoxicity and
enable future studies to uncover mechanisms to suppress toxicity. S. pombe is a novel
model organism with unique advantages that is compatible with existing models, allowing for cross-validation between models, and insight into new and potentially critical
information.
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